US Plows $354m Into Phlow
Start-Up Is Awarded Contract To Manufacture Essential Medicines In US
Executive Summary
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.
You may also be interested in...
Environmental Regulations May Create Barriers To Onshoring More Rx Manufacturing
The House Ways and Means Committee may take more of a kitchen sink approach to addressing drug shortages than other congressional committees that have been primarily focused on paying for quality. Hearing witnesses said Congress must follow through on funding incentives for US onshoring.
Civica Rx COO McCoy To Step Into CEO Role From 1 June
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
Phlow Enters Deal To Expand CDMO Services With Continuous Manufacturing
Phlow partners to provide continuous manufacturing research and development services for active pharmaceutical ingredients and registered starting materials. The company has also announced the appointment of Malcolm Berry as a senior consultant at the company’s R&D team.